IMPLANET SA Inactive Instrument
Implanet SA Stock Euronext Paris
Equities
ALIMP
FR0010458729
Medical Equipment, Supplies & Distribution
| Sales 2022 | 8.03M 8.75M | Sales 2023 | 7.45M 8.12M | Capitalization | 2.62M 2.86M |
|---|---|---|---|---|---|
| Net income 2022 | -3M -3.27M | Net income 2023 | -6M -6.54M | EV / Sales 2022 | 1.41 x |
| Net Debt 2022 | 6.27M 6.83M | Net Debt 2023 | 5.9M 6.44M | EV / Sales 2023 | 1.15 x |
| P/E ratio 2022 |
-0.97
x | P/E ratio 2023 |
-0.37
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 87.76% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 12-11-26 | |
David Dieumegard
DFI | Director of Finance/CFO | - | 15-08-31 |
Yvanna Peigné
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 10-03-30 | |
| Chief Executive Officer | - | 12-11-26 | |
| Director/Board Member | - | 14-06-09 |
Implanet SA designs, produces, and sells medical implants and devices used in orthopedic surgery. The group's products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, anchors, etc. Net sales break down by activity as follows:
- spine surgery (94.9%);
- knee surgery and arthroscopy (1%).
The balance of net sales (4.1%) concerns the medical equipment distribution activity.
Net sales are distributed geographically as follows: France (47.1%), Europe/Middle East/Africa (14.3%), the United States (18.5%) and other (20.1%).
Calendar
2024-09-09
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -1.48% | 12.12B | |
| -20.95% | 6.91B | |
| +58.12% | 6.72B | |
| -28.32% | 4.12B | |
| +9.22% | 3.46B | |
| -17.21% | 2.45B | |
| -18.86% | 1.88B | |
| -28.80% | 1.57B | |
| -38.19% | 1.45B |
